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Background/aim: The purpose of this study is to investigate the prognostic significance of lower uterine segment (LUS) involvement
in endometrial cancer (EC).
Materials and methods: We reviewed the patients who were operated at our institution between July 2007 and March 2015 with the
diagnosis of EC. Tumors localized in the corpus and involving the LUS or localized entirely in the LUS formed Group A, while tumors
in the uterine corpus without LUS involvement formed Group B. Clinicopathological characteristics and survival of the patients were
compared in both groups.
Results: A total of 500 patients were included in the study. There were 139 patients who had tumors involving the LUS and formed
Group A, while 361 patients with endometrial tumors in the uterine corpus without LUS involvement formed Group B. We did not
detect a significant difference between survival of the patients in group A and group B (78 months vs. 87 months, respectively; P > 0.05).
Conclusion: We found that LUS involvement was not an independent prognostic factor for poor survival, but it is associated with other
poor prognostic factors such as deep myometrial invasion, uterine serosal involvement, lymphovascular space invasion, lymph node
metastasis and higher FIGO grade.
Key words: Endometrial cancer, lower uterine segment, prognosis, survival

1. Introduction
Endometrial cancer (EC) is the fourth most common
cancer among women and the most common malignancy
of the female genital system (1). EC arises from the uterine
corpus (UC), but in 3%–6% of EC cases, the localization
of the tumor is the lower uterine segment (LUS) (2–4).
LUS-originated tumors are located between the UC and
the uterine cervix and show histological characteristics of
both parts, which sometimes complicates the differential
diagnosis of EC and cervical adenocarcinomas when
determination of the primary tumor is essential for
further treatment and prognosis (2). Tumors originating
from the LUS or involving the LUS also differ from UC
tumors with thin mucosal and myometrial layers and
poor hormonal response to estrogen (5). Since EC cases
that originate from the LUS are rare, a small number of
studies have compared the characteristics of LUS tumors
with UC-originated tumors. There have been conflicting
reports on the effect of LUS involvement as a prognostic
factor in endometrial cancer. In this study we aimed to
* Correspondence: ozmurat@gmail.com
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compare the clinical and pathological characteristics and
overall survival of endometrial carcinoma cases involving
the LUS with UC tumors without LUS involvement.
2. Materials and methods
This study was conducted at Zekai Tahir Burak Women’s
Health Training and Research Hospital, Ankara, Turkey,
after obtaining the approval of the institutional ethics
board. The clinical records and pathology reports of the
patients who were operated on with the diagnosis of
endometrial carcinoma in the Gynecologic Oncology
Department of our hospital between July 2007 and March
2015 were reviewed retrospectively.
Inpatient and outpatient records, operation and
pathology reports, and clinical and demographic data of
the patients were reviewed. The pathological records of
patients included in this study were reviewed and tumor
localizations were identified. Tumor localizations were
grouped as UC tumors with LUS involvement and UC
without LUS involvement.
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During the study period, the surgical management
protocol for endometrial carcinoma of our department
changed; patients with histopathologically proven
endometrial carcinoma before 2013 underwent
comprehensive surgical staging including total abdominal
hysterectomy (TAH), bilateral salpingo-oophorectomy
(BSO), omental biopsy, peritoneal cytology, and pelvic
and paraaortic lymph node dissection, regardless of
intraoperative frozen section. However, after 2013,
women with nonendometrioid histologic subtypes, >1/2
myometrial invasion (MI), grade 3 disease, or tumor size >2
cm in the frozen section result of the hysterectomy specimen
were surgically staged in the above-mentioned manner,
while the women without any these above-mentioned risk
factors had only TAH-BSO and peritoneal cytology. A
gynecologic pathologist in the Pathology Department of
our institution reviewed all the specimens. Patients who
were operated on at other institutions and patients with
postoperative diagnosis of cervical adenocarcinoma or
tumor suspicion of other primary locations were excluded.
Follow-up was carried out in our Gynecologic Oncology
Department every 3 months in the first 2–3 years, every 6
months for 2 years, and then annually. Clinicopathological
characteristics of the patients including age, serum CA125 levels, tumor staging according to the International
Federation of Gynecology and Obstetrics (FIGO), and
survival of patients were determined. Pathological findings
including tumor histology, FIGO grade, tumor diameter,
cytology positivity, lymphovascular space invasion (LVSI),
and MI status were also recorded.
Patients were classified into two groups based on LUS
involvement. Tumors localized in the UC and involving
the LUS or localized entirely in the LUS formed Group A,
while tumors in the UC without LUS involvement formed
Group B.
Patients with gross cervical or vaginal involvement,
deep MI, grade 3 disease, or positive LVSI were consulted
for radiation therapy, while patients with nonendometrioid
subtypes, positive lymph nodes, or metastatic disease were
referred to platinum-based chemotherapy for the adjuvant
setting.
All data were analyzed using SPSS 18.0 (SPSS Inc.,
Chicago, IL, USA). Differences between groups were
assessed using the chi-square test, Fisher’s exact test, and
the Mann–Whitney U test for categorized variables and
Student’s t-test for continuous variables. We used the
Kaplan–Meier method to estimate the overall survival
of the patients, and overall survival rates were compared
using the log-rank test. Cox proportional hazard analysis
was used to assess the prognostic significance of the
different characteristics. The Cox regression model was
used in multivariate analysis. Risk of death was expressed
as the hazard ratio (HR) with the 95% confidence interval
(CI). P < 0.05 was considered significant.

3. Results
There were 527 patients operated on with the diagnosis of
endometrial carcinoma at our institution from July 2007
through March 2015. Tumor localizations were defined in
the pathology reports of 500 patients out of 527 while 27
patients were excluded from the analysis. Median followup time was 34 months.
The median age of the patients was 59 years. Thirtyseven patients (7.4%) had TAH with BSO and peritoneal
washing, while the remaining 463 patients (92.6%)
underwent a systematic surgical staging including pelvic
and paraaortic lymph node dissection up to the renal
veins and omental biopsy. Fifty-two patients (10.4%) had
positive pelvic nodes, while 40 patients (8%) had positive
paraaortic nodes.
There were 139 patients who had tumors involving
the LUS and formed Group A, while 361 patients with
endometrial tumors in the UC without LUS involvement
formed Group B. There were 14 patients (2.8%) who had
tumors limited to only the LUS, while 125 patients (25%)
had tumors involving both the UC and LUS. No mortality
occurred among that subgroup of patients and these
patients were included in Group A. The average age at
diagnosis, serum Ca-125 levels, histological subtypes, and
peritoneal cytology results were similar in both groups.
However, larger tumor diameter (>5 cm), higher FIGO
grade (Grade 3), deep MI (>1/2 MI) and serosal invasion,
LVSI, adnexal involvement, and pelvic and paraaortic
lymph node involvement were more common for patients
in Group A. Clinicopathological characteristics of the
patients are summarized in Table 1.
Overall survival was slightly inferior in Group A
compared to Group B (median survival 78 vs. 87 months,
95% CI, respectively); 5-year estimated overall survivals
were 82.3% and 80.1%, respectively, but this was not
statistically significant (P > 0.05). Figure 1 shows survival
curves for Groups A and B. We further stratified patients
according to histological subtypes as endometrioid
and nonendometrioid subtypes. In patients with the
endometrioid subtype, median overall survivals were 84
vs. 90 months for Group A and Group B, respectively (95%
CI, P > 0.05), while 5-year estimated overall survivals were
84.5% vs. 86.4% for Groups A and B, respectively (logrank test, P > 0.05); neither was statistically significant.
In patients with nonendometrioid histology, median
overall survivals were 59 vs. 75 months for Groups A and
B, respectively (95% CI, P > 0.05), while 5-year estimated
overall survivals were 59.8% vs. 65.1% for Groups A and B,
respectively (log-rank test, P > 0.05), and again it was not
statistically significant. Figures 2A and 2B show survival
curves of Groups A and B according to histological
subtypes.
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Table 1. Comparison of endometrial carcinoma with isolated LUS tumors and uterine corpus tumors without LUS involvement.

Variables

Group A
N = 139,
LUS involvement

Group B
N = 361,
without LUS involvement

P-value

Age at diagnosis (mean years, ± SD)

58.2 ± 9.7

57.9 ± 9.6

>0.05

Tumor diameter (mean, cm)

4.7 ± 2.3

2.8 ± 1.6

<0.01

Ca-125 (U/mL, mean)

31.8

27.5

>0.05

FIGO Grade
1
2
3

63 (45.3%)
36 (25.9%)
40 (28.7%)

236 (65.3%)
73 (20.2%)
52 (14.4%)

<0.0001

Histological subtype
Endometrioid
Serous
Clear
Mucinous
Mixed type
Carcinosarcoma
Others

105 (75.5%)
8 (5.7%)
13 (9.3%)
2 (1.4%)
8 (5.7%)
2 (1.4%)
1 (0.7%)

284 (78.6%)
21 (5.8%)
13 (3.6%)
6 (1.6%)
30 (8.3%)
4 (1.1%)
3 (0.8%)

>0.05

Myometrial invasion (N, %)
No invasion
MI <1/2
MI ≥1/2

6 (4.3%)
65 (46.7%)
68 (48.9%)

58 (16%)
213 (59%)
89 (24.6%)

<0.001

Serosal involvement (N, %)
Positive
Absent

17 (12.2%)
122 (87.7%)

12 (3.3%)
349 (96.6%)

<0.001

LVSI (N, %)
Positive
Negative

58 (41.8%)
81 (58.2%)

73 (20.2%)
288 (79.8%)

<0.001

Peritoneal cytology (N, %)
Positive
Negative

17 (12.2%)
122 (87.7%)

28 (7.7%)
333 (92.3%)

>0.05

Adnexal involvement
Adnexa positive
Adnexa negative

16 (11.5%)
123 (88.5%)

21 (5.8%)
340 (94.2%)

>0.05

Pelvic LN metastasis (N, %)
Positive
Negative

25 (18%)
114 (82%)

27 (7.5%)
334 (92.5%)

<0.001

Paraaortic LN metastasis (N, %)
Positive
Negative

19 (13.6%)
120 (86.4%)

21 (5.8%)
340 (94.2%)

<0.005

Status
Dead
Alive

20 (14.4%)
119 (85.6%)

33 (9.1%)
328 (90.9%)

>0.05

LUS: Lower uterine segment; MI: myometrial invasion; LVSI: lymphovascular space invasion; LN: lymph node.
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Figure 1. Overall survival curves for Groups A and B, all patients.

In univariate analysis, nonendometrioid histologic
subtype, older age of the patients (>65 years), larger tumor
size (>5 cm), FIGO Grade 3 histology, advanced stage of
the disease, peritoneal cytology positivity, lymph node
involvement, LVSI, and MI were significantly related
to poor survival. However, LUS involvement was not
associated with decreased overall survival in univariate
analyses. In the multivariate analysis, MI (HR 3.22, 95%
CI 1.42–7.29, P < 0.005) and tumor grade (HR 6.57, 95%
CI 3.59–12.04, P < 0.001) were the only independent
prognostic factors for survival (Table 2).
4. Discussion
The LUS is the anatomical and histological landmark
of transition of endometrial tissue to endocervical
epithelium between the UC and the cervix. In our patient
cohort, 27.8% of the endometrial cancer patients had
tumors involving the LUS. This case-comparison study is
the first report that assesses the clinical and pathological
features of endometrial carcinoma regarding the tumor
localization in the LUS. There have been limited studies
in the literature considering the LUS involvement in
cases of endometrial carcinoma with conflicting results,
hypothesizing that endometrial carcinoma of the LUS may

be a worse prognostic factor. In our study we separated the
cases into two groups as tumors in the UC involving the
LUS or tumors entirely in the LUS (Group A) and tumors
in the UC without LUS involvement (Group B), and we
found that LUS involvement was not an independent
prognostic factor for poor survival, but it is associated with
other poor prognostic factors such as deep MI, uterine
serosal involvement, LVSI, lymph node metastasis, and
higher FIGO grade.
The thickness of the myometrial wall in the LUS is less
than that in the UC, and also the lymphatic drainage differs.
Therefore, the behavior of LUS tumors was hypothesized
to be more diversified than that of UC tumors with their
clinical and pathological characteristics.
Endometrial carcinoma is basically defined as type 1
or type 2 cancer (6). Carcinoma of the LUS mainly shows
characteristics of type 2 endometrial cancer, seen in elder
women, whereas endometrial atrophy plays a role instead
of estrogen exposure and it is presumed to be due to weak
response of the thin endometrial layer of the LUS to estrogen
and shows similar immunohistochemical characteristics
with type 2 endometrial cancer (2,7). Conversely, Westin
et al. reported that patients with LUS-isolated tumors were
significantly younger than the ones with UC tumors and
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Figure 2. A) Overall survival curves for Groups A and B, patients with endometrioid subtype. B) Overall
survival curves for Groups A and B, patients with nonendometrioid subtype.
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Table 2. Factors that affect survival in Group A and Group B in
multivariate analysis.
HR (CI)

P-value

MI

3.22 (1.42–7.29)

<0.005

LVSI

1.216 (0.45–3.278)

0.700

Tumor size >5 cm

1.889 (0.899–3.966)

0.093

Grade 3 histology

6.57 (3.59–12.04)

<0.001

LUS involvement

1.29 (0.88–2.27)

>0.05

HR: Hazard ratio; MI: myometrial invasion; LVSI: lymphovascular
space invasion; LUS: lower uterine segment.

the prevalence of LUS tumors was 9% in patients under
50 years of age (3). However, in our patient cohort, the age
of the patients and the histological subtypes of the tumors
were similar in both groups. Interestingly, we found that
5-year estimated survival rates in Groups A and B were
quite similar for the endometrioid subtype (84.5% vs
86.4%), while the difference in survival rates was larger in
Groups A and B for the nonendometrioid subtypes (59.8%
vs 65.1%).
Phelan et al. (8) studied 98 women with stage 1
endometrial cancer with and without LUS involvement
and reported that there was no significant difference
between patients with or without LUS involvement
in terms of grade, histology, LVSI, deep MI, pelvic
recurrence, and 5-year disease-free survival. However,
the authors included only stage 1 endometrial cancer
patients and the prevalence of LUS involvement was 19%.
Similar to these results, Mayr et al. (9) reported that tumor
grade, histology, LVSI, and MI were similar between
the stage 1 endometrial tumors of 106 patients with and
without LUS involvement. In contrast, Hachisuga et al.
reported that LUS involvement was correlated with lower
median age, higher grade, deeper MI, and less favorable
histology, but their study population included only 12
patients (4). Kizer et al. (10) evaluated 481 patients and

reported decreased disease-free survival in patients with
LUS involvement. In our study, we found slightly lower,
but not statistically significant, overall survival in patients
with LUS involvement compared to tumors without LUS
involvement. Our study population was larger than those
of previous studies, and while previous studies involved
only stage 1 tumors, we included patients with all stages
of tumors, which may have altered the survival rates. In
nonendometrioid tumors, LUS involvement diminished
survival slightly more compared to endometrioid subtypes,
but the effect was still nonsignificant.
Doll et al. (11) investigated tumor size and tumor
localization of 208 patients with early-stage and highgrade tumors. Similar to our results, they noted that LUS
tumors were associated with pelvic and paraaortic nodal
involvement. The authors (11) also reported an association
between tumor size and nodal involvement; comparable
with our results, tumors involving the LUS were also larger
in diameter.
Westin et al. (3) suggested that tumors arising in the
LUS were a subtype of endometrial cancer. In fact, several
studies reported that tumors involving the LUS were
equivalent to UC tumors in regards to survival and did
not imply a worse prognosis (8,12). We found that tumors
with LUS involvement were associated with other poor
prognostic factors such as deep MI, serosal involvement,
LVSI, lymph node metastasis, and higher FIGO grade, but
it was not an independent poor prognostic factor alone
without other accompanying poor prognostic factors.
However, LUS tumors were considered as a poor
prognostic factor with increased risk of pelvic recurrences
and, even in the absence of other risk factors, adjuvant
therapy was administered in some centers (9). Further
studies will reveal the prognostic impact of LUS
involvement on intra- and postoperative treatment plans.
Just as decisions about lymph node dissection are made
based on preoperative and intraoperative histopathological
findings using modified Mayo Clinic criteria in most
institutions, LUS involvement in frozen sections may
influence lymph node dissection decisions for the surgeon
(13).
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